Eli Lilly Reports Phase 1 Ovarian Cancer Combination Results

Eli Lilly reported Phase 1 results for sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer, with a 33-woman cohort showing a 79% confirmed objective response rate and a 100% disease control rate among 29 evaluable patients.

Eli Lilly & Co (NYSE: LLY) reported Phase 1 results for sofetabart mipitecan (Sofe-M) plus bevacizumab in platinum-sensitive ovarian cancer.

The combination produced a 79% confirmed objective response rate and a 100% disease control rate.

The Phase 1 cohort included 33 women. The response rates come from evaluable patients with measurable disease. We read these as early observations, not established clinical benefit.

A confirmed objective response rate of 79% or higher held in both PARP inhibitor-treated and PARP inhibitor-naive patients. Median duration of response and median progression-free survival had not been reached at median follow-ups of 6.2 and 10.2 months, respectively.

The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across platinum-resistant and platinum-sensitive ovarian cancer. We think those ongoing trials, rather than this cohort, could be the test of whether the combination delivers clinical benefit.

The confirmed objective response rate reached 79.3% among the 29 evaluable patients with measurable disease at the July 6, 2026, data cutoff.

• Six of those patients had a complete response, 20.7% of the group.
• Another 17 had a partial response, 58.6% of the group.
• Patients had received a median of three prior systemic regimens.
• 67% had received a prior PARP inhibitor.
• 70% had received prior bevacizumab.

Epistaxis (nosebleeds) and nausea were the most common adverse events of any grade, each occurring in 73% of patients.

• Neutropenia was the most common Grade 3 or higher treatment-emergent adverse event, affecting 42% of patients.
• Grade 3 or higher anemia occurred in 24% of patients.
• Dose reductions occurred in 42% of patients.
• 6% of patients discontinued treatment due to an adverse event.
• Any-grade neuropathy occurred in 9% of patients, with no Grade 3 or higher events.